TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Aberrant epidermal growth factor receptor (EGFR) signaling drives non-small cell lung cancer (NSCLC) progression and resistance to tyrosine kinase inhibitors (TKIs).
• Acquired resistance to EGFR-TKIs necessitates novel therapeutic strategies targeting alternative mechanisms in NSCLC.

Purpose of the Study:

• To investigate the role of tribbles pseudokinase 3 (TRIB3) in EGFR stability and non-small cell lung cancer (NSCLC) pathogenesis.
• To explore the potential of targeting the TRIB3-EGFR interaction as a therapeutic strategy for NSCLC.

Main Methods:

• Immunoprecipitation and Western blotting to analyze TRIB3-EGFR interaction and EGFR post-translational modifications.
• Cell-based assays to assess the impact of TRIB3 on EGFR stability, downstream signaling, and NSCLC stemness.
• In vitro studies using a stapled peptide to disrupt the TRIB3-EGFR interaction and evaluate its effect on NSCLC progression and chemosensitivity.

Main Results:

• Elevated TRIB3 expression positively correlates with EGFR stability and promotes NSCLC progression and stemness.
• TRIB3 interacts with EGFR, recruiting PKCα and WWP1 to induce specific phosphorylation and ubiquitination events that enhance EGFR stability and recycling.
• Disruption of the TRIB3-EGFR interaction using a stapled peptide accelerates EGFR degradation, attenuates NSCLC progression, and sensitizes cells to chemotherapy.

Conclusions:

• TRIB3 plays a critical role in stabilizing EGFR, contributing to NSCLC progression and therapeutic resistance.
• Targeting the TRIB3-EGFR interaction and promoting EGFR degradation represents a novel and promising therapeutic avenue for EGFR-driven NSCLC.